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Abstract 
A Stability indicating Reverse-Phase liquid chromatographic method for the simultaneous estimation 
of HCTZ, LOSA and AMLO was developed. The chromatographic assay involves the use of SUPELCO LC-8-
DB column (15 cm x 4.6 mm, 5 µm) with a simple mobile phase composition of Buffer (monobasic Potassium 
Dihydrogen phosphate of 0.025 M having pH 3.7): Acetonitrile (60:40) at a flow rate of 1mL/min with U.V 
detection at wavelength of 232 nm. The method showed good linearity in the concentration range of 4-40 
μg/mL for HCTZ and 2-22 μg/mL for AMLO and 15-150 μg/mL for LOSA. The proposed method was also 
successfully applied to 20 tablets of marketed formulation (Trilopace). The developed method was 
successfully validated as per the ICH guidelines for following parameters. Accuracy, precision, ruggedness, 
robustness, system suitability tests, etc. The RSD for system precision was found to be 0.89-0.49 for HCTZ, 
AMLO, and LOSA and for method precision 1.0-1.4 for HCTZ, AMLO, and LOSA. The average percentage 
recoveries 99.75, 99.88, 98.93 for HCTZ, AMLO, LOSA which was in good agreement with labeled amount 
of Pharmaceutical formulation. The stability indicating capacity was tested by accelerated degradation of 
marketed formulation in acidic (0.1 N HCL), basic (0.1 N NaOH), , Oxidative (3% H2O2), Thermal (80
0
C) 
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1. Introduction 
The technique HPLC is so called because of 
its improved performance over the classical column 
chromatography. The technique basically involves the 
use of porous material as a stationary phase and the 
liquid mobile phase is pumped into the column under 
high pressure. The development of this technique is 
attributed to the small particle size of stationary 
phase. As the particle size is small the resistance to 
the flow of mobile phase is very high that is the 
reason why the high pressure is recommended.
1, 2
 The 
stability indicating assays are defined as validated 
quantitative analytical methods that can detect the 
changes with time in the chemical, physical, or 
microbiological properties of the drug substance and 
drug product, and that are specific so that the contents 
of active ingredient, degradation products, and other 
components of interest can be accurately measured 
without interference. Stress testing is the main tool 
that is use to predict stability problems, develop 
analytical methods, and identify degradation product 
and pathways. Stress testing is likely to be carried out 
on single batch of the drug substance. It should 
include the effect of temperature in 10ºC increments 
(Eg.50ºC, 60ºC etc). Above that for accelerated 
testing, humidity (Eg. 75% RH or greater) where 
appropriate oxidation and photolysis on the drug 
substance. The testing should also evaluate the 
susceptibility of the drug substance to hydrolysis 
across a wide range of pH values when in solution or 
suspension. Photostability testing should be an 
integral part of stress testing. The review of 
literature
9-13, 17-19 
suggested that very few stability 
indicating assay method for the above combination 
has been reported so the present work is undertaken 
with following objectives    The present work is 
undertaken with an objective to develop economical, 
simple, accurate, precise and reproducible stability 
indicating assay method for estimation of these drugs 
in their combined dosage form. Amlodipine besylate 
[Figure 1] chemically is 3-ethyl 5-methyl 2-[(2-
aminoethoxy) methyl]-4- (2-chlorophenyl)-6- methyl-
1,4-dihydropyridine-3,5-dicarboxylate.  It is a white 
to off-white crystalline powder and Solubility Slightly 
soluble in water, freely soluble in Methanol, sparingly 
soluble in ethanol. While the losartan potassium 
[figure 2] chemically is (2-butyl-4-chloro-1-{[2'-(1H-
tetrazol-5-yl) biphenyl-4-yl]methyl}-1H-imidazol-5-
yl)methanol. It is white to off-white free flowing 
crystalline powder and it is freely soluble in water, 
soluble in alcohols, and slightly soluble acetonitrile 
and methyl ethyl ketone. 
While hydrochlorothiazide is [Figure 3] 
chemically is 6-chloro-1,1-dioxo-3,4-dihydro-2H-
1,2,4-benzothiadiazine-7-sulfonamide  and it is white 
crystalline powder  and it is slightly soluble in Water 
methanol and Soluble in Acetone
14-16, 5
.  
 
Figure 1: Chemical structure of amlodipine besylte 
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Figure 2: Chemical structure of losartan 
potassium 
. 
Figure 3: chemical structure of 
hydrochlorothiazide  
 
2. Experimentals 
Chemicals and reagents: The gift sample of 
Hydrochlorothiazide, Amlodipine besylate and 
Losartan Potassium was provided by ZIM 
Laboratories, Nagpur. The tablet formulation of 
Hydrochlorothiazide, Amlodipine besylate and 
Losartan Potassium was purchased from the local 
market. All the chemicals used of HPLC Grade (Merk 
Ltd., Mumbai) and double distilled water was used 
for mobile phase preparation. 
Instrument: An HPLC system of shimadzu with 
pump- LC 2010 CHT and Detector- PDA with 
Software- LC Solution (Shimadzu) with column of 
SUPELCO LC-8-DB (15 cm x 4.6 mm, 5 µm) and 
isocratic elution is performed using Buffer 
(monobasic Potassium Dihydrogen phosphate of 
0.025 M having pH 3.7) : Acetonitrile (60: 40) as 
mobile phase. At flow rate of 1 ml/min at detection 
wavelength of 232 nm. 
Preparation of Mobile Phase: Prepare a mixture of 
Acetonitrile of HPLC grade and Buffer in 40:60 ratio 
respectively. This was selected as common solvent 
for preparation of stock solution and further dilutions 
from stock solutions were made in the same mixture 
of Acetonitrile and Buffer in the ratio 40:60. 
Preparation of Buffer: Dissolve 3.4 gms of 
monobasic Potassium Dihydrogen phosphate in 1000 
ml of HPLC water, and adjust pH to 3.7 with Ortho 
Phosphoric Acid. 
Preparation of Standard Solution: Weigh 
accurately 31.25 mg of Hydrochlorothiazide, 17.36 
mg of Amlodipine Besylate equivalent to Amlodipine 
12.5 mg and 125 mg of Losartan Potassium working 
standard in a 100ml volumetric flask and dissolve by 
sonication in sufficient mobile phase then make up 
the volume by mobile phase.  
Preparation of working standard solution: Dilute 
5.0 ml of this solution to 50 ml with mobile phase to 
get the working concentration of amlodipine besylate, 
losartan potassium and hydrochlorothiazide.  
Selection of detection wavelength: from the overlain 
spectra the detection wavelength selected was 232 
nm.  
Figure 4: overlain spectra of LOSA, HCTZ, and AMLO 
 
Linearity study: From the standard stock solution 
sufficient volume of aliquots were transferred to 10 
ml volumetric flask to get the concentration in range 
of 4-40µg/ml for HCTZ, 2-22 µg/ml for AMLO and 
15-150 µg/ml for LOSA. Volume of 20µl of each 
sample was injected with the help of Hamilton 
Syringe. All measurements were repeated five times 
for each concentration and calibration curve was 
constructed by plotting the peak area versus the drug 
concentration. 
Analysis of Marketed formulation: Weighed 
accurately 20 tablets and determine the average 
weight then crushed the tablets into fine powder. 
Transfer powder equivalent to 125 mg Losartan 
Potassium in 100 ml volumetric flask and dissolve by 
sonication for 10 minutes and make up the volume to 
100 ml with mobile phase stir the solution for 30 
minutes. Centrifuge and dilute 5.0 ml of this solution 
to 50.0 ml with mobile phase.  Equal volume (20 L) 
of standard and sample solution was injected 
separately after equilibrium of stationary phase. The 
chromatograms were recorded and the response i.e. 
peak area of major peaks were measured. The content 
of Hydrochlorothiazide, Amlodipine Besylate and 
Losartan Potassium were calculated by comparing a 
sample peak with that of standard. 
 
Method validation
6
:  
1. Accuracy: It was done by recovery study using 
standard addition method at 80%, 100% and 120% 
level; known amount of AMLO, HCTZ and LOSA 
standard was added to preanalysed sample and 
subjected to the proposed HPLC method. The percent 
recovery was then calculated by using following 
formula 
                                        Ew - B 
           % Recovery =     ----------   X 100 
                                            C 
Where, Ew = Total drug estimated (mg) 
B= Amount of drug contributed by 
preanalysed capsule powder (mg)                                        
             C= Weight of pure drug added (mg). 2.  
Precision:  
2.1 System precision: System Precision was 
determined by taking five replicate injections of 
Standard solution into HPLC system.  Weigh 
accurately 31.25 mg of Hydrochlorothiazide, 17.36 
mg of Amlodipine Besylate equivalent to Amlodipine 
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12.5 mg and 125 mg of Losartan Potassium working 
standard in a 100ml volumetric flask and dissolve by 
sonication in sufficient mobile phase then make up 
the volume by mobile phase. Dilute 5.0 ml of this 
solution to 50 ml with mobile phase i.e; 31.25 mcg/ml 
of Hydrochlorothiazide 17.36 mcg/ml of Amlodipine 
Besylate and 125 mcg/ml of Losartan Potassium.  
2.2 Method precision: Method Precision was 
determined by six sample solution of 
Hydrochlorothiazide Amlodipine Besylate and 
Losartan Potassium Tablets were prepared and 
analyzed on the same day by HPLC method. 
2.3 Intermediate precision (Ruggedness): Six 
sample solution of HCTZ, AMLO and LOSA Tablets 
was prepared as per described method and analyzed 
by different analyst using same make of different 
HPLC column. The percentage label claim of HCTZ, 
AMLO and LOSA in HCTZ, AMLO and LOSA 
tablet was calculated and reported along with the 
standard deviation (sample) and % RSD of the six 
samples. 
3. Specificity: Specificity is the ability to assess 
unequivocally the analyte in the presence of 
components that may be expected to be present in the 
formulation. 
Placebo Interference study: The solution of 
analytical placebo (containing all the excipients 
except HCTZ, AMLO and LOSA) was prepared 
according to the sample preparation procedure and 
injected in to HPLC. To identify the interference by 
these excipients, Standard solution and Marketed 
formulation of HCTZ, AMLO and LOSA were 
analyzed by the developed method. 
Placebo Preparation: Weigh accurately 571.68 mg 
of Placebo in a 100ml volumetric flask and dissolve 
by sonication in sufficient mobile phase then make up 
the volume by mobile phase. Dilute 5 ml of this 
solution to 50 ml with mobile phase and mix. Filter 
the solution through 0.45µm filter and inject the clear 
filtrate. 
Standard solution preparation: Weigh accurately 
31.25 mg of HCTZ, 17.36 mg of AMLO equivalent to 
12.5 mg of AMLO and 125 mg of LOSA working 
standard in a 100ml volumetric flask and dissolve by 
sonication in sufficient mobile phase then make up 
the volume by mobile phase. Dilute 5.0 ml of this 
solution to 50 ml with mobile phase i.e 31.25 mcg/ml 
of Hydrochlorothiazide 17.36 mcg/ml of AMLO and 
125 mcg/ml of Losartan Potassium.   
Sample solution preparation: Weighed accurately 
20 tablets and determine the average weight then 
crushed the tablets into fine powder. Transfer powder 
equivalent to 125 mg Losartan Potassium in 100 ml 
volumetric flask and dissolve by sonication for 10 
minutes and make up the volume to 100 ml with 
mobile phase stir the solution for 30 minutes. 
Centrifuge and dilute 5.0 ml of this solution to 50.0 
ml with mobile phase and mix. Filter the solution 
through 0.45µm filter and inject the clear filtrate. 
4. Linearity and Range: For Drug release 
determination the concentration of 
Hydrochlorothiazide, Amlodipine Besylate and 
Losartan Potassium is 31.25 mcg/ml, 17.36 mcg/ml 
and 125 mcg/ml respectively. So the working Range 
of analytes was set between 18 mcg/ml to 43 mcg/ml 
for Hydrochlorothiazide, 10 mcg/ml to 24 mcg/ml for 
Amlodipine Besylate and 75 mcg/ml to 175 mcg/ml 
for Losartan Potassium to show the Linearity standard 
solutions 18,25,31,37 and 43 mcg/ml for 
Hydrochlorothiazide, 10,13,17,20 and 24 mcg/ml for 
Amlodipine Besylate and 75, 100, 125, 150 and 175 
mcg/ml for Losartan Potassium corresponding to 
approximately 60 % to 140 % of the test 
concentration where prepared as per described 
method. 
5. Robustness: The tablet sample of HCTZ, AMLO 
and LOSA was analyzed using proposed method after 
a deliberate change in detection wavelength for 
estimation by ±2 nm. 
6. Stability of Analytical Solution: Prepare standard  
and sample solutions as per the method and Inject one 
standard and sample preparation initially at 0 hr and 
after specified time-intervals i.e after 4hrs, 8 hrs and 
12 hrs Monitor the pattern of chromatogram at the 
pre-determined intervals and compare it against the 
initial pattern. Calculate the assay at each time 
interval. The stability of analytical solution is checked 
for Drugs up to 12 hrs. 
7. System Suitability Study: Weigh accurately 31.25 
mg of Hydrochlorothiazide, 17.36 mg of Amlodipine 
Besilate equivalent to Amlodipine 12.5 mg and 125 
mg of Losartan Potassium working standard in a 
100ml volumetric flask and dissolve by sonication in 
sufficient mobile phase then make up the volume by 
mobile phase. Dilute 5.0 ml of this solution to 50 ml 
with mobile phase. 
Force Degradation Studies
4
:  
Preparation of Sample Solution Stock: Weighed 
accurately 20 tablets and determine the average 
weight then crushed the tablets into fine powder. 
Transfer powder equivalent to 125 mg Losartan 
Potassium in 100 ml volumetric flask and dissolve by 
sonication for 10 minutes and make up the volume to 
100 ml with mobile phase stir the solution for 30 
minutes. Centrifuge and filter the solution through 
0.45 µm membrane filterate dilute 5.0 ml of this 
solution to 50.0 ml with mobile phase. 
1. Acid Degradation: 5 ml of sample stock solution 
was pipette out in 50 ml Volumetric flask and it was 
subjected to acid stress degradation by treating the 
sample with 5 ml of 0.1 N HCL and the solution was 
kept at room temperature for 8 hour. Neutralize with 
0.1 N NAOH and make up the volume to 50 ml with 
mobile phase and injected into the HPLC system.  
2. Base Degradation: 5 ml of sample stock solution 
was pipette out in 50 ml Volumetric flask and it was   
subjected to Alkali stress degradation by treating the 
sample with 5 ml of 0.1 N NAOH and the solution 
was kept at room temperature for 8 hour. Neutralize 
with 0.1 N HCL and make up the volume to 50 ml 
with mobile phase and injected into the HPLC 
system. 
3. Oxidative Degradation: 5 ml of sample stock 
solution was pipette out in 50 ml Volumetric flask 
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and it was subjected to Peroxide stress degradation by 
treating the sample with 5 ml of 3% H2O2 and the 
solution was kept at room temperature in dark area for 
8 hour and make up the volume to 50 ml with mobile 
phase and injected into the HPLC system. 
4. Thermal Degradation: 5 ml of sample stock 
solution was pipette out in 50 ml Volumetric flask, 
make up the volume to 50 ml with  mobile phase and 
then the solution was subjected to Thermal stress 
degradation by heating the sample on boiling water 
bath at 80ºc for 8 hours and injected into the HPLC 
system. 
5. Photo Degradation: Photo degradation studies 
were carried out on solid dosage form (fine Tablet 
powder). The sample in a petri plate was spread as a 
thin layer (1 mm) and exposed to direct UV radiation 
for 24 hours in UV chamber. The withdrawn samples 
were dissolving and then diluted with mobile phase as 
per sample preparation. 
 
3. Results and Discussion 
HPLC method development and optimization: The 
finally optimized chromatographic conditions are.  
Column SUPELCO LC-8-DB column 
(15 cm x 4.6 mm, 5 µm) 
Mobile Phase
  
Buffer (monobasic Potassium Dihydrogen 
phosphate of 0.025 M having pH 3.7) : 
Acetonitrile (60: 40) 
Detection 
wavelength 
232 nm 
Injection volume                20 µl 
Flow rate                            1 ml/min 
Temperature 30°C 
 
Figure 5: Optimized chromatogram of HCTZ, LOSA and 
AMLO 
 
2. Linearity 
   
Table 1: Results of Linearity studies of LOSA, HCTZ and AMLO
 
Sr. No. Concentration in  g/ml Peak Area 
HCTZ AMLO LOSA HCTZ AMLO LOSA 
1 4 2 15 271651 74553 1094766 
2 8 4 30 543422 148106 2289533 
3 12 6 45 825361 223659 3284299 
4 16 10 60 1087011 288213 4279066 
5 20 12 75 1353750 372766 5473832 
6 24 14 90 1578502 446319 6668599 
7 28 16 105 1903233 521872 7663365 
8 32 18 120 2248012 595426 8658132 
9 36 20 135 2485754 670979 9852898 
10 40 22 150 2817505     747827 10847665 
Y  
NLT:  0.995 Correlative Coefficient (r
2
) 
             
Figure 5: Calibration curve of HCTZ 
 
Figure 7: Calibration curve of LOSA 
 
       
 
 
 
              
           
       
 
 
 
Figure 6: Calibration curve of AMLO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Chromatogram of Marketed formulation 
 
Calibration Curve for HCTZ
y = 70145x - 31769
R
2
 = 0.9984
0
500000
1000000
1500000
2000000
2500000
3000000
0 10 20 30 40 50
Conc. (mcg/ml)
A
r
e
a HCTZ
Linear (HCTZ)
 
Standard Calibration Curve for AMLO
y = 37433x - 2792.7
R
2
 = 0.9998
0
200000
400000
600000
800000
0 5 10 15 20 25
Conc. (mcg/ml)
A
r
e
a
AMLO
Linear (AMLO)
 
Calibration Curve for LOSA
y = 72298x + 46666
R
2
 = 0.9996
0
2000000
4000000
6000000
8000000
10000000
12000000
0 50 100 150 200
Conc. (mcg/ml)
A
r
e
a LOSA
Linear (LOSA)
Research Article                                                                                         Charde et al /2014 
 
31 
 
Analysis of Marketed Formulation: The marketed 
formulation was Trilopace manufactured by sun 
pharmaceuticals.  
Content: 
1) Hydrochlorothiazide    : 12.5 mg 
2) Amlodipine Besylate     : 5 mg 
3) Losartan Potassium      : 50 mg 
Average weight    : 292.2mg 
 
     
 
 
 
 
 
Table 2: Results of marketed formulation analysis 
Sr. 
No 
Weight of std.(mg) 
Weight  
of 
sample 
(mg) 
Peak area of standard Peak area of sample % Label claim 
HCTZ AMLO LOSA HCTZ AMLO LOSA HCTZ AMLO LOSA HCTZ AMLO LOSA 
1  
 
32 
 
 
17.5 
 
 
125.9 
738.7 
 
2171510 
 
596426 
 
8778331 
2118090 590519 8660513 98.27 98.69 98.56 
2 736.0 2111385 588360 8648859 98.19 99.39 98.07 
3 730.8 2125548 584203 8617588 98.62 98.69 98.41 
 
 
Method Validation:  
1. Accuracy:                         
Table 3: Recovery studies of HCTZ 
 
Table 4: Recovery studies of AMLO 
 
Table 5: Recovery studies of LOSA 
 
2. Precision:  
2.1 System precision: The results indicate that there 
is no variation in area counts of five consecutive 
injections. The RSD values are less than 2.0 % and 
are well within the limits.  
                                          
 
 
% Level of 
Standard 
Weight of Working Standard (mg) 
added its dilution (ml) 
Area at 232 
nm 
Standard 
Recovered 
(mg) 
% 
Recover 
Mean 
Recover 
% 
RSD 
80 25.0/100/5/50 
1713040 
 
25.1175 
 
100.47 
99.75 0.6227 
1703150 
1723146 
100 31.3/100/5/50 
2141300 
31.1028 99.37 2101299 
2121301 
`120 37.6/100/5/50 
2569560 
37.3819 99.42 2529438 
2549558 
% Level of 
Standard 
Weight of Working 
Standard (mg) added its 
dilution (ml) 
Area at 232 
nm 
Standard 
Recovered 
(mg) 
% Recover 
Mean 
Recover 
% RSD 
 
80 
 
13.9/100/5/50 
472415 
 
13.9105 
 
100.07 
99.88 0.3589 
475321 
477252 
 
100 
 
17.4/100/5/50 
590519  
17.3091 
 
99.47 591810 
590807 
 
120 
 
20.9/100/5/50 
708622  
20.9230 
 
100.11 717360 
717358 
% Level of 
Standard 
Weight of Working 
Standard (mg) added and its 
dilution (ml) 
Area at 232 
nm 
Standard 
Recovered 
(mg) 
% Recover 
Mean 
Recover 
% RSD 
 
80 
 
100/100/5/50 
6928410 
98.9399 98.93 
98.93 0.0058 
6917269 
6937271 
 
100 
 
125/100/5/50 
8660513 
123.6754 98.94 8654189 
8664088 
 
120 
 
150/100/5/50 
10392615 
148.4099 98.93 10389897 
10391908 
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Table 6: System precision data of HCTZ, AMLO and LOSA 
Injection 
No. 
Area at 232 nm for 
Hydrochlorothiazide 
Area at 232 nm for 
Amlodipine Besylate 
Area at 232 nm for 
Losartan Potassium 
Limit 
1 2191200 597904 8834082  
 
 
NMT 2.0 % 
 
 
 
 
2 2189471 600107 8815351 
3 2174004 596944 8758132 
4 2151882 592328 873672 
5 2150994 594847 8748020 
Mean 2171510 596426 8778331 
+_ SD 19511 2970 43564 
% RSD 0.898 0.498 0.496 
 
2.2 Method Precision: Six sample weights of 
Hydrochlorothiazide, Amlodipine Besylate and 
Losartan Potassium Tablets by same analyst in same 
laboratories on same day. The analysis results are 
ranging from 99.07 to 99.34 for Hydrochlorothiazide, 
100.97 % to 101.14 % for Amlodipine Besylate and 
100.05 % to 100.15 % for Losartan Potassium. The % 
deviation from mean Value for six samples is less 
than 2.0 %. 
 
Table 7: Results of method precision 
 
2.3 Intermediate Precision (Ruggedness): The 
result are ranging from 98.46 % to 101.21 % for 
Hydrochlorothiazide, from 99.51 % to 99.98 % for 
Amlodipine Besylate and from 98.53 % to 99.17 % 
for Losartan Potassium the % deviation from mean 
assay value for six samples are not more than 2.0 %. 
Table 8: Results of Intermediate precision 
 
3. Specificity: For the Chromatographic method does 
not show interference of excipients in chromatogram 
at the λ-max of the analytes or at the detection 
wavelength of subject analytes. In this case of HCTZ, 
AMLO and LOSA the detection wavelength is 232 
nm. 
 
Figure 9: Chromatogram of Placebo shows there are no peaks 
at the retention time of HCTZ, AMLO and LOSA in the 
chromatograph indicates that there is no placebo interference 
 
Figure 10: Chromatogram of HCTZ, LOSA and AMLO 
working standard 
 
           Figure 11: Chromatogram of Marketed formulation 
 
 
 
 
 
 
 
 
 
Sr. 
No. 
Sample 
Weight (g) 
 
Area at 232 
 
% Assay 
% Deviation Form Mean Assay Value 
HCTZ AMLO LOSA HCTZ AMLO LOSA HCTZ AMLO LOSA 
1 0.7315 2102187 593360 8698271 98.50 100.14 98.27 -0.021 -0.43 +1.69 
2 0.7313 2099371 592104 8684515 98.39 99.96 99.11 -0.1 -0.25 +0.85 
3 0.7311 2124008 600844 8808122 99.57 99.65 100.55 -1.28 +0.06 -0.59 
4 0.7317 2101872 593338 8706062 98.45 100.11 99.30 -0.16 -0.4 +0.66 
5 0.7319 2060974 583857 8547020 96.51 98.47 97.46 +1.78 +1.24 +2.5 
6 0.7322 2100738 592951 8692276 98.33 99.98 99.08 -0.04 -0.27 +0.88 
Mean 98.29 99.71 99.96  
 
NMT 2.0 % 
± SD 0.9887 0.6358 1.040 
% RSD 1.0059 0.6376 1.0402 
Sr. 
No. 
Sample 
Weight (g) 
Area at 232 % Assay % Deviation Form Mean Assay 
Value 
HCTZ AMLO LOSA HCTZ AMLO LOSA HCTZ AMLO LOSA 
1 0.7310 2116832 589218 8630050 99.25 99.51 98.53 +0.27 +0.29 +0.43 
2 0.7308 2099349 591821 8660513 98.46 99.98 98.91 +1.06 -0.18 +0.05 
3 0.7315 2108090 590519 8690976 98.77 99.66 99.16 +0.75 +0.14 -0.20 
4 0.7320 2131877 592201 8698271 99.82 99.88 99.17 -0.3 -0.08 -0.21 
5 0.7318 2127310 591321 8650361 99.63 99.76 98.65 -0.11 +0.04 +0.31 
6 0.7321 2161800 593361 8715188 101.21 100.06 99.35 -1.69 -0.26 -0.39 
Mean 99.52 99.80 98.96  
NMT 2.0 % +- SD 0.9713 0.2056 0.3224 
% RSD 0.9759 0.2059 0.3258 
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4. Linearity and Range:  
Table 9: Linearity and range study of HCTZ 
Sr. 
No. 
Weight of Working Standard (mg) added and its 
dilution (ml) 
Concentration 
(mcg/ml) 
Mean Area Count 
At 232 nm 
Limit 
1 31.30/100/3/50 18.78 1312999  
 
 
NMT:0.995 
2 31.30/100/4/50 25.04 1737298 
3 31.30/100/5/50 31.30 2181399 
4 31.30/100/6/50 37.56 2604798 
5 31.30/100/7/50 43.82 3141098 
Y  70301 X 
Correlation Coefficient (r2) 0.9971 
 
Figure 12: Calibration curve of HCTZ 
 
 
 
 
 
 
 
 
 
 
 
Table 10: Linearity and range study of AMLO 
Sr. 
No. 
Weight of Working Standard (mg) added and its 
dilution (ml) 
Concentration 
(mcg/ml) 
Mean Area Count 
At 232 nm 
Limit 
1 17.4/100/3/50 10.4 367397  
 
 
NMT:0.995 
2 17.4/100/4/50 13.92 477496 
3 17.4/100/5/50 17.40 598596 
4 17.4/100/6/50 20.88 724695 
5 17.4/100/7/50 24.36 843794 
Y 34610 X 
Correlation Coefficient (r
2
) 0.9995 
Figure 13: Calibration curve of AMLO 
  
 
 
 
 
 
 
 
Table 11: Linearity and range study of LOSA 
Sr. 
No. 
Weight of Working Standard (mg) added and its 
dilution (ml) 
Concentration 
(mcg/ml) 
Mean Area Count 
At 232 nm 
Limit 
1 125/ 100/ 3/ 50 75 5366988  
 
 
NMT:0.995 
2 125/ 100/ 4/ 50 100 7124984 
3 125/ 100/ 5/ 50 125 8778981 
4 125/ 100/ 6/ 50 150 10434990 
5 125/ 100/ 7/ 50 175 12392973 
Y 70476 X 
Correlation Coefficient (r
2
) 0.9988 
 
Figure 14: Calibration curve of LOSA 
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5. Robustness:   
Table 12: Results of Robustness study 
 
 
 
 
 
 
 
 
6. Stability of Analytical solution:  
Table 13: Results of stability evaluation for HCTZ 
Time (h) Peak Area of Standard 
Solution 
Peak Area of 
Sample Solution 
% Estimation 
0 hrs 2172004 2117080 98.20 
4 hrs 2170010 2116900 98.29 
8 hrs 2168471 2136765 99.28 
12 hrs 2155320 2158520 100.60 
Mean 99.09 
S.D. 1.1178 
%R.S.D. 1.1280 
Table 15: Results of stability evaluation of LOSA 
Time (h) Peak Area of 
Standard Solution 
Peak Area of 
Sample Solution 
% Estimation 
Initial 8776321 8660412 98.59 
4 Hrs 8774092 8660269 98.61 
8 Hrs 8770221 8689649 98.99 
12 Hrs 8761532 8638718 98.51 
Mean 98.68 
S.D. 0.2143 
%R.S.D. 0.2172 
Table 14: Results of stability evaluation 
Time (h) Peak Area of 
Standard 
Solution 
Peak Area of 
Sample 
Solution 
% Estimation 
Initial 596528 590518 98.68 
4 Hrs 596489 590764 98.56 
8 Hrs 596121 589980 99.68 
12 Hrs 595734 588620 100.88 
Mean 99.45 
S.D. 1.0774 
%R.S.D. 1.0834 
Table 16: Results of system suitability for HCTZ
Sr. No. Area Reproducibility Retention Time Tailing Factor 
(Asymmetry) 
Theoretical Plates Resolution 
1 2189472 3.602 1.801 2995.527 - 
2 2174882 3.578 1.805 2972.766 - 
3 2162726 3.558 1.807 2963.596 - 
4 2155432 3.546 1.806 2963.114 - 
5 2160294 3.554 1.797 3013.302 - 
Mean 2168561 3.567 1.803 2981.661 - 
% RSD 0.6322 0.642 0.232 0.739 - 
Limit NMT 2.0 % NMT 1 % NMT 2 NMT 2000 NLT 1.5 
Table 17: Results of system suitability for AMLO 
Sr. No. Area Reproducibility Retention Time Tailing Factor 
(Asymmetry) 
Theoretical Plates Resolution 
1 597906 7.905 1.078 2166.912 13.585 
2 596468 7.886 1.069 2181.686 13.607 
3 593140 7.842 1.064 2164.146 13.631 
4 592081 7.828 1.055 2211.021 13.700 
5 591552 7.821 1.069 2207.671 13.700 
Mean 594229 7.856 1.067 2186.287 13.645 
% RSD 0.4722 0.469 0.787 1.011 0.389 
Limit NMT 2.0 % NMT 1 % NMT 2 NMT 2000 NLT 1.5 
 
Sr. 
No. 
Change in wavelength 
(± 2 nm) 
% Estimation 
HCTZ AMLO LOSA 
1 230 98.06 98.51 98.20 
2 232 98.36 98.92 98.35 
3 234 98.12 98.23 98.28 
Mean 98.18 98.55 98.28 
S.D. 0.1587 0.3470 0.0750 
%R.S.D. 0.1617 0.3521 0.0763 
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Table 18: Results of system suitability for LOSA
  
System Suitability Parameters:  
1. Relative standard deviation of the area of analytes peaks in standard chromatograms should not be more 
than 2.0 %.  
2. Theoretical plates of analytes peak in STD chromatograms should not be less than 2000. 
3. Tailing Factor (Asymmetry) of analytes peaks in Standard Chromatograms should less than 2. 
Force Degradation Studies: 
1. Acid Degradation:  
Figure 15: Chromatogram of Acid degradation. 
 
 
 
Table 19: Results of Acid degradation 
 
Stress Condition Drugs % Degrdation % Assay of Drugs 
after degradition 
Acid degradation: 
5 ml of 0.1N HCL at 
room temp. for 1 hr. 
HCTZ 6.21 93.79 
AMLO 5.74 94.26 
LOSA 5.30 94.70 
2. Base Degradation:  
Figure 16: Chromatogram of Base Degradation 
 
 
Table 20: Results of Base degradation 
Stress Condition Drugs % 
Degrdation 
% Assay of Drugs 
after degradition 
Alkali degradation : 
5 ml of 0.1N HCL at 
room temp. for 1 hr. 
HCTZ 6.21 93.79 
AMLO 5.74 94.26 
LOSA 5.30 94.70 
Sr. No. Area Reproducibility Retention Time Tailing Factor 
(Asymmetry) 
Theoretical Plates Resolution 
1 8834084 10.504 1.613 7959.575 7.217 
2 8812217 10.478 1.613 7980.377 7.247 
3 8773530 10.432 1.612 7976.077 7.266 
4 8750822 10.405 1.619 7966.598 7.265 
5 8751663 10.406 1.618 8004.281 7.294 
Mean 8784463 10.445 1.615 8778.331 7.258 
% RSD 0.4244 0.424 0.202 0.496 0.392 
Limit NMT 2.0 % NMT 1 % NMT 2 NMT 2000 NLT 1.5 
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3. Oxidative Degradation:  
Figure 17: Chromatogram of oxidative degradation 
 
Table 21: Results of oxidative degradation 
Stress Condition Drugs % 
Degrdation 
% Assay of Drugs after 
degradition 
Oxidative degradation: 
5 ml of 3% H2O2 at room temperature for 
1 hr. 
HCTZ 8.24 91.76 
AMLO 7.76 92.24 
LOSA 5.68 94.32 
4. Thermal Degradation:  
Figure 18: Chromatogram of thermal degradation 
 
Table 22: Results of thermal degradation 
Stress Condition Drugs % Degrdation % Assay of Drugs after degradition 
Thermal degradation 800c for 8 hrs HCTZ 8.24 91.76 
AMLO 7.76 92.24 
LOSA 5.68 94.32 
5. Photo Degradation:  
Figure 19: Chromatogram of Photo degradation  
 
Table 23: Results of Photo degradation 
Stress Condition Drugs 
% 
Degradation 
% Assay of 
Drugs after 
degradition 
Photo degradation: 
Solid dosage form exposed to direct UV 
radiation for 24 hours in  UV chamber. 
HCTZ 7.31 92.69 
AMLO 6.84 93.16 
LOSA 5.37 94.63 
 
4. Conclusion 
The proposed method was validated as Per 
the ICH Guidelines. The proposed method also 
showed the good resolution between HCTZ, AMLO 
and LOSA with run time of 10.5 min. The method is 
very simple and rapid and no where involves 
complicated sample preparation and mobile phase 
preparation. Also the proposed method showed good 
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specificity and selectivity in order to determine 
HCTZ, AMLO and LOSA in the presence of their 
degradation products. The linearity and 
reproducibility data of the drugs carried out by this 
method showed that no major interference is caused 
in the estimation of the drugs. Therefore the method 
can be use for routine quality control of these drugs.  
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